Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.
Jacob Laubach, MD, MPP
Advertisement
Articles by Jacob Laubach, MD, MPP
Advertisement
Latest Updated Articles
Dr. Laubach on the Efficacy of Daratumumab in MyelomaDecember 10th 2013
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
5